Safety Pharmacology Services

Safety pharmacology addresses a question distinct from toxicology. Toxicology asks what damage a compound causes at high or repeated doses. Safety pharmacology asks whether a compound disturbs the function of vital organ systems at doses within or near the therapeutic range, in the absence of any structural damage at all. A compound can be entirely free of histopathological findings and still produce a functional effect that precludes clinical use.

Altogen Labs supports safety pharmacology assessment of central nervous system, respiratory, and cardiovascular function alongside toxicology and IND-enabling programs, with scope defined per program. To discuss requirements for a specific compound, request a quote.

Organ systems assessed

Central nervous system evaluation covers behavior, motor activity, coordination, reflexes, and body temperature, assessed to a structured observation framework rather than by informal note. The value of a structured battery is that it detects effects an investigator watching for a specific outcome would not look for.

Respiratory assessment addresses respiratory rate, tidal volume, and derived measures where the compound class or an observed signal warrants it.

Cardiovascular assessment addresses heart rate, blood pressure, and electrocardiographic parameters. The specific endpoints and the methods used are determined per program rather than applied uniformly, and where a specialized assessment falls outside the scope available it is identified at the planning stage rather than late.

Timing relative to exposure

Functional effects are frequently transient and concentration dependent, appearing near peak exposure and resolving as concentration falls. An assessment made at a fixed convenient timepoint may fall entirely outside the window in which an effect occurs, producing a clean result from a compound that produces a substantial transient effect.

Assessment timing is therefore set against the exposure profile from pharmacokinetic characterization rather than by convention, with observations concentrated around expected peak concentration. Where exposure has not yet been characterized, that work precedes the safety pharmacology assessment rather than running in parallel with it.

Applied examples

CNS observation battery. A compound with central penetration is assessed across a structured behavioral and motor battery at multiple timepoints spanning the exposure profile, with observations scored against defined criteria by an observer blinded to treatment group.

Dose-related functional effect. Observations are made across three dose levels, establishing whether a functional signal is dose related and whether it appears below, at, or above the dose producing efficacy, which determines whether the finding constrains development.

Integration with tolerability. Functional assessment is combined with clinical pathology and histopathology in the same animals, distinguishing a functional effect with no structural correlate from one accompanied by tissue change.

Scope of claims

Altogen Labs describes the safety assessment it supports rather than claiming that every assay named in general regulatory guidance is performed. Where a program requires a specialized assessment outside the available scope, that is stated at the planning stage so it can be arranged elsewhere and the overall package remains complete.

Conduct and reporting

Observation schedule, scoring criteria, dose levels, and their relationship to the anticipated exposure profile are defined before initiation, and observers are blinded to treatment group where the endpoint involves judgment. Reports state the methods used, the timepoints assessed relative to dosing, per-animal observations, and the relationship between any finding and dose or exposure. All procedures are conducted under active IACUC protocols. GLP standards are applied where a study is formally designated as GLP.

Send compound class, intended clinical dose range, and organ systems of concern, or request a quote.